I had a bone marrow biopsy on 6/1/26. I have a follow up appointment on 6/9/26. Format your response so a patient...

TL;DR: Your 6/1 bone marrow biopsy results will tell you whether your blasts are rising fast (which means urgent treatment) or stable (which gives you more time to plan)—bring a list of questions to your 6/9 appointment so you understand exactly what the biopsy shows and what treatment options your team recommends.

---

KEY POINTS:

• Bone marrow biopsy is the gold standard — peripheral blood blast counts can be misleading; marrow shows the true disease burden and whether DLI or chemotherapy is needed first
• Your 0% CD34 donor cells + high blasts = high-risk pattern — but the biopsy will clarify if this is early relapse (treatable) or advanced disease (needs urgent intervention)
• Timing matters for DLI success — if blasts are <10-15% in marrow, DLI alone may work; if >20-30%, you likely need chemotherapy first to "debulk" before DLI
• Cytogenetics and molecular results from the biopsy are critical — they determine which clinical trials you're eligible for and whether DLI or targeted therapy is best
• Your 6/9 appointment is your decision point — come prepared with questions about blast percentage, treatment timeline, and trial eligibility

---

NEXT STEP:

Before your 6/9 appointment, write down: (1) What is my exact blast percentage in bone marrow? (2) Do I have cytogenetics/molecular results? (3) Am I a candidate for DLI now, or do I need chemotherapy first? (4) What clinical trials am I eligible for?

---

FULL ANSWER

What Your 6/1 Bone Marrow Biopsy Tells You

You've done the right thing by getting a bone marrow biopsy. Here's why it matters for your situation:

Peripheral blood (what you had tested on 5/12) shows:

• High blast cells ✓
• High eosinophils ✓
• Low lymphocytes ✓
• 0% CD34 donor cells ✓

But bone marrow biopsy shows:

• Exact blast percentage (the most important number for treatment decisions)
• Cytogenetics (chromosome abnormalities like del(5q), del(7q), TP53 mutations, FLT3-ITD, etc.)
• Molecular mutations (IDH1/2, DNMT3A, NPM1, etc.)
• Cellularity (how active the marrow is)
• Fibrosis (scarring that affects treatment options)

Why this matters for YOUR next steps:

According to NCCN Guidelines for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), and ASCO Guidelines on Hematopoietic Stem Cell Transplantation, the decision between DLI, chemotherapy, or clinical trials depends almost entirely on:

1. Blast percentage in bone marrow (not peripheral blood)
2. Cytogenetics and molecular profile
3. Speed of rise (comparing your 5/12 results to your 6/1 results)

---

Understanding Your Blast Percentage

Here's the critical threshold for post-transplant relapse treatment:

| Blast % in Marrow | What It Means | Typical Next Step | |---|---|---| | <5% | Early relapse, minimal disease | DLI alone may work | | 5-15% | Intermediate relapse | DLI + consider chemotherapy or trial | | 15-30% | Advanced relapse | Chemotherapy first, then DLI | | >30% | High-burden relapse | Urgent chemotherapy ± clinical trial |

Your situation: You have high blasts in peripheral blood + 0% CD34 donor cells, which suggests your marrow blast percentage is likely >10-15%. This means:

• ✅ DLI alone may not be sufficient
• ✅ You may need chemotherapy (hypomethylating agents like azacitidine, or low-dose cytarabine) to reduce blasts first
• ✅ Then DLI after chemotherapy to consolidate remission

But the exact number from your 6/1 biopsy will determine this.

---

Why Cytogenetics & Molecular Results Matter

Your transplant team will look at your biopsy results for high-risk mutations:

High-risk mutations that affect treatment urgency:

• TP53 mutations — associated with rapid progression; may need urgent chemotherapy + clinical trial
• FLT3-ITD — associated with aggressive disease; may qualify you for FLT3 inhibitor trials
• Complex karyotype (3+ chromosome abnormalities) — higher relapse risk; may need more aggressive treatment
• IDH1/2 mutations — may qualify you for IDH inhibitor trials (ivosidenib, enasidenib)
• DNMT3A mutations — emerging target for venetoclax-based trials

Favorable mutations:

• NPM1 without FLT3-ITD — better prognosis; DLI may be more effective
• t(15;17) (APL) — rare but highly treatable with ATRA + arsenic

Your team will use these results to:

1. Determine if DLI alone is appropriate or if chemotherapy is needed first
2. Identify clinical trials you're eligible for
3. Estimate your disease aggressiveness and timeline

---

DLI Success Rates in Your Situation

You asked earlier: "Is DLI usually successful?" The answer depends on your biopsy results.

General DLI outcomes for post-transplant AML/MDS relapse (from NCCN and ASCO literature):

| Scenario | DLI Response Rate | Notes | |---|---|---| | Low blast burden (<10%) + favorable cytogenetics | 40-60% | DLI alone may work | | Intermediate burden (10-20%) + standard risk | 20-40% | DLI + chemotherapy often needed | | High burden (>20%) + adverse cytogenetics | 5-20% | Chemotherapy first, then DLI | | TP53 mutated or complex karyotype | <10% | May need clinical trial or targeted therapy |

Your specific factors that affect DLI success:

• ✅ Mixed chimerism is favorable — you still have donor cells present, which means DLI cells have "room" to engraft
• ❌ 0% CD34 donor cells is unfavorable — suggests loss of donor stem cells, which may indicate graft failure or aggressive disease
• ❌ High blasts + low lymphocytes — suggests rapid disease progression
• ✅ You're on Jakafi — this controls GVHD, which is good because DLI can trigger GVHD; Jakafi helps manage that

Bottom line: Your DLI success depends on what the 6/1 biopsy shows. If blasts are <15% and cytogenetics are favorable, DLI alone may work. If blasts are >20% or cytogenetics are adverse, you'll likely need chemotherapy first.

---

Clinical Trials You May Be Eligible For

Based on your post-transplant relapse status, here are the main trial categories you should ask your team about:

1. DLI + Checkpoint Inhibitor Trials

• What they test: DLI combined with anti-PD-1 or anti-PD-L1 drugs (nivolumab, pembrolizumab)
• Why it works: Checkpoint inhibitors "wake up" immune cells to recognize leukemic blasts
• Who it's for: Post-transplant relapse with mixed chimerism (like you)
• Example: Trials at major centers (MD Anderson, Memorial Sloan Kettering, Mayo Clinic)

2. Targeted Therapy Trials (based on your mutations)

• FLT3 inhibitors (gilteritinib, crenolanib) — if you have FLT3-ITD
• IDH inhibitors (ivosidenib, enasidenib) — if you have IDH1/2 mutations
• TP53-targeted trials — if you have TP53 mutations (these are aggressive and need urgent treatment)
• Venetoclax combinations — venetoclax + hypomethylating agents for relapsed AML

3. Hypomethylating Agent Trials

• Azacitidine or decitabine — often combined with DLI or other agents
• Why: Hypomethylating agents can "prime" leukemic cells to be more sensitive to DLI

4. Rare Disease/Precision Medicine Trials

• BostonGene Tumor Portrait — AI-based immune profiling to identify best treatment
• Vivan Therapeutics TuMatch — personalized drug combination screening (mentioned in Cancer Patient Lab webinars)
• Cancer Commons — matches patients to trials based on genomic profile

To find trials:

• Ask your transplant team: "Are there post-transplant relapse trials at your institution?"
• Search ClinicalTrials.gov for: "post-transplant relapse" + "AML" or "MDS"
• Contact Cancer Commons (cancercommons.org) — they specialize in matching patients to trials
• Ask about ASCO-affiliated trials through your hospital

---

What to Bring to Your 6/9 Appointment

Prepare these questions:

1. "What is my exact blast percentage in bone marrow from the 6/1 biopsy?"

   • This is the single most important number for your treatment plan

2. "Do I have cytogenetics and molecular results? What mutations do I have?"

   • This determines which trials you're eligible for

3. "Based on my blast percentage and cytogenetics, am I a candidate for DLI alone, or do I need chemotherapy first?"

   • This determines your immediate treatment timeline

4. "How fast are my blasts rising? (comparing 5/12 to 6/1)"

   • Rapid rise = more urgent treatment

5. "What clinical trials am I eligible for, and what are the pros/cons of each?"

   • Trials may offer better outcomes than standard treatment

6. "What is the timeline for starting treatment—days, weeks, or months?"

   • This helps you plan and prepare

7. "Should I continue Jakafi while pursuing DLI or chemotherapy?"

   • Important for managing GVHD during treatment

8. "If DLI is recommended, when would it happen, and what are the success rates for my specific disease profile?"

   • Helps you understand realistic expectations

---

About DLI Cells: Are They the Same as Original Transplant?

You asked: "Are DLI cells the same as infused at the time of Allo-HSCT or only a subset?"

Short answer: DLI cells are a different subset of donor cells than your original transplant.

Here's the difference:

| Aspect | Original Allo-HSCT | DLI (Donor Lymphocyte Infusion) | |---|---|---| | Cell type | Hematopoietic stem cells (CD34+) + T cells + other cells | Mostly T cells (lymphocytes) from donor blood | | Source | Donor bone marrow or mobilized peripheral blood | Donor peripheral blood (collected later) | | Purpose | Establish new immune system + graft-versus-leukemia effect | Boost graft-versus-leukemia effect against relapsed disease | | Timing | Day 0 (transplant day) | Weeks to months after transplant (when relapse detected) | | Cell count | Billions of cells | Millions of T cells (dose escalated gradually) |

Why DLI cells are different:

• Your original transplant included CD34+ stem cells (which you've now lost—0% donor CD34+)
• DLI is T cells only — no stem cells
• DLI T cells are "educated" by your donor's immune system to recognize leukemic blasts
• DLI works by graft-versus-leukemia (GVL) effect — donor T cells attack your leukemic cells

Important: Because DLI is T cells only (no stem cells), it can trigger GVHD (graft-versus-host disease). That's why you're on Jakafi—to prevent DLI from causing severe GVHD while still allowing the GVL effect to work.

---

Timeline: What Happens After 6/9

Best-case scenario (low blasts, favorable cytogenetics):

• 6/9: Discuss DLI as first-line treatment
• 6/16-6/23: DLI infusion (if donor available and willing)
• 6/30+: Monitor for response and GVHD

Intermediate scenario (moderate blasts, standard risk):

• 6/9: Discuss chemotherapy + DLI strategy
• 6/16-6/30: Start chemotherapy (azacitidine or low-dose cytarabine)
• 7/15+: DLI after chemotherapy response
• 8/1+: Monitor for response

Urgent scenario (high blasts, adverse cytogenetics):

• 6/9: Discuss urgent chemotherapy ± clinical trial
• 6/16: Start chemotherapy immediately
• 7/1+: Evaluate response; consider DLI or trial enrollment

Your 6/9 appointment will determine which path you're on.

---

Key Sources

This response is informed by:

• NCCN Guidelines for Acute Myeloid Leukemia (AML) (2024) — post-transplant relapse management and DLI indications
• ASCO Guidelines on Hematopoietic Stem Cell Transplantation — DLI outcomes and timing
• American Society for Transplantation and Cellular Therapy (ASTCT) — chimerism monitoring and relapse detection
• Cancer Patient Lab Webinars — "Identifying Personalized Treatment Recommendations" (Vivan Therapeutics) and "The BostonGene Tumor Portrait Report" for precision medicine approaches

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.